In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma

Citation
O. Andersson et al., In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma, J ALLERG CL, 103(4), 1999, pp. 595-600
Citations number
44
Categorie Soggetti
Clinical Immunolgy & Infectious Disease",Immunology
Journal title
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
ISSN journal
00916749 → ACNP
Volume
103
Issue
4
Year of publication
1999
Pages
595 - 600
Database
ISI
SICI code
0091-6749(199904)103:4<595:IVMOGR>2.0.ZU;2-Q
Abstract
Background: In vivo regulation of the glucocorticoid receptor (GR) by gluco corticoids provides a means of modulating sensitivity of targeted cells. Objective: We sought to determine the in vivo modulation of GR mRNA express ion by fluticasone propionate (FP) in subjects with mild asthma. Methods: Ten atopic asthmatic subjects were treated with FP 250 mu g twice daily for 4 weeks. Before and after treatment, the patients underwent fiber optic bronchoscopy with endobronchial biopsy and sampling of venous blood f or measurements of GR mRNA levels, A solution hybridization assay was used for quantitative analysis of GR mRNA. In addition, a 24-hour urinary cortis ol excretion and an adrenocorticotropic hormone test before and after treat ment with FP were performed. Results: A high interindividual variation in GR mRNA expression was seen. H owever, we detected a significant reduction of the GR mRNA levels in the en dobronchial biopsy specimens after FP treatment (36.6 +/- 23.1 and 25.0 +/- 10.9 amol GR mRNA/mu g RNA, respectively; P < .01). In the peripheral bloo d lymphocytes an even more striking downregulation of the GR by its cognate ligand was documented (30.3 +/- 26.5 and 8.8 +/- 5 amol GR mRNA/mu g RNA, respectively; P < .001), possibly reflecting differences in glucocorticoid sensitivity between tissues. A small but significant reduction of the 24-ho ur urinary cortisol excretion was observed (233 +/- 109 and 157 +/- 66 nmol /L, respectively; P < .01), whereas the feedback regulation of glucocortico id synthesis by means of the hypothalamic-pituitary-adrenal axis as assesse d by the adrenocorticotropic hormone test remained normal after treatment w ith FP. Conclusion: The results in this study confirm the potency of the inhaled co rticosteroid FP and provide evidence for a considerable tissue-specific int erindividual variation in the expression of the GR.